Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxy 210

Next Previous
Drug Profile

Oxy 210

Alternative Names: Oxy-210

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MAX BioPharma
  • Developer MAX BioPharma; National Institute of Infectious Diseases
  • Class Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Small molecules; Sterols
  • Mechanism of Action Hedgehog cell signalling pathway inhibitors; Transforming growth factor beta inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical COVID 2019 infections; Non-alcoholic steatohepatitis
  • No development reported Cancer

Most Recent Events

  • 28 Oct 2024 Oxy 210 is still in preclinical trials for Non-alcoholic steatohepatitis in the US (MAX BioPharma pipeline October 2024)
  • 24 Oct 2024 MAX BioPharma announces intention to submit IND to US FDA for Non-alcoholic steatohepatitis
  • 24 Oct 2024 Pharmacodynamic data from a preclinical study in Non-alcoholic steatohepatitis released by MAX BioPharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top